Oragenics (NYSE:OGEN – Get Free Report) and XOMA (NASDAQ:XOMA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.
Volatility and Risk
Oragenics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Oragenics and XOMA, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oragenics | 0 | 0 | 0 | 0 | 0.00 |
| XOMA | 0 | 0 | 3 | 0 | 3.00 |
Insider and Institutional Ownership
18.7% of Oragenics shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 10.1% of Oragenics shares are held by insiders. Comparatively, 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Oragenics and XOMA”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oragenics | $40,000.00 | 90.47 | -$20.66 million | ($7.07) | -0.04 |
| XOMA | $9.71 million | 32.41 | -$40.83 million | ($3.48) | -7.68 |
Oragenics has higher earnings, but lower revenue than XOMA. XOMA is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Oragenics and XOMA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oragenics | N/A | -2,087.95% | -486.56% |
| XOMA | -151.34% | -24.95% | -9.64% |
Summary
XOMA beats Oragenics on 9 of the 14 factors compared between the two stocks.
About Oragenics
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
